H.C. Wainwright initiated coverage on Editas Medicine with a new price target

4/28/25 8:37:22 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

H.C. Wainwright initiated coverage of Editas Medicine with a rating of Buy and set a new price target of $3.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EDIT

Date	Price Target	Rating	Analyst
4/28/2025	$3.00	Buy	H.C. Wainwright
12/16/2024		Neutral → Underweight	Analyst
12/13/2024		Buy → Neutral	Chardan Capital Markets
12/13/2024		Buy → Hold	Truist
12/13/2024	$11.00 → $3.00	Buy → Hold	Stifel
12/11/2024	$7.00 → $4.00	Overweight → Equal Weight	Wells Fargo
11/25/2024	$13.00 → $1.00	Buy → Underperform	BofA Securities
11/6/2024		In-line → Outperform	Evercore ISI